Stocks
ABIOMED Financial Statements (ABMD) |
||||||||||
| ABIOMEDsmart-lab.ru | % | 2021 | 2022 | 2022 | LTM ? | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 21.05.2021 | 30.09.2021 | 31.12.2021 | 31.03.2022 | 20.05.2022 | 03.11.2022 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 847.5 | 1 032 | 1 032 | 1 083 | |||||
| Operating Income, bln rub | 229.6 | 140.7 | 372.7 | 254.1 | ||||||
| EBITDA, bln rub | ? | 246.9 | 190.6 | 400.8 | 287.4 | |||||
| Net profit, bln rub | ? | 225.5 | 136.5 | 136.5 | 281.3 | |||||
| OCF, bln rub | ? | 274.6 | 285.4 | 160.5 | ||||||
| CAPEX, bln rub | ? | 53.4 | 35.8 | 27.3 | ||||||
| FCF, bln rub | ? | 221.2 | 249.6 | 133.2 | ||||||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | |||||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0 | ||||||
| OPEX, bln rub | 456.1 | 586.9 | 586.9 | 624.3 | ||||||
| Cost of production, bln rub | 161.9 | 188.2 | 188.2 | 204.4 | ||||||
| R&D, bln rub | 121.9 | 163.4 | 163.4 | 170.1 | ||||||
| Interest expenses, bln rub | 0.000 | 0.000 | 49.8 | 94.2 | ||||||
| Assets, bln rub | 1 494 | 1 530 | 1 593 | 1 673 | 1 673 | 1 697 | ||||
| Net Assets, bln rub | ? | 1 330 | 1 385 | 1 433 | 1 503 | 1 503 | 1 540 | |||
| Debt, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Cash, bln rub | 583.7 | 650.6 | 669.2 | 758.6 | 758.6 | 820.4 | ||||
| Net debt, bln rub | -583.7 | -650.6 | -669.2 | -758.6 | -758.6 | -820.4 | ||||
| Ordinary share price, rub | 318.7 | 325.5 | 359.2 | 331.2 | 331.2 | 377.5 | ||||
| Number of ordinary shares, mln | 45.1 | 45.1 | 45.4 | 45.4 | ||||||
| Market cap, bln rub | 14 387 | 0 | 0 | 14 952 | 15 053 | 17 126 | ||||
| EV, bln rub | ? | 13 804 | -651 | -669 | 14 194 | 14 295 | 16 306 | |||
| Book value, bln rub | 1 204 | 1 265 | 1 315 | 1 387 | 1 381 | 1 417 | ||||
| EPS, rub | ? | 5.00 | 3.02 | 3.00 | 6.20 | |||||
| FCF/share, rub | 4.90 | 0.00 | 5.49 | 2.94 | ||||||
| BV/share, rub | 26.7 | 30.7 | 30.4 | 31.2 | ||||||
| EBITDA margin, % | ? | 29.1% | 18.5% | 38.8% | 26.5% | |||||
| Net margin, % | ? | 26.6% | 13.2% | 13.2% | 26.0% | |||||
| FCF yield, % | ? | 1.54% | 0.00% | 0.00% | 0.00% | 1.66% | 0.78% | |||
| ROE, % | ? | 17.0% | 0.00% | 0.00% | 9.08% | 9.08% | 18.3% | |||
| ROA, % | ? | 15.1% | 0.00% | 0.00% | 8.16% | 8.16% | 16.6% | |||
| P/E | ? | 63.8 | 109.5 | 110.3 | 60.9 | |||||
| P/FCF | 65.0 | 60.3 | 128.6 | |||||||
| P/S | ? | 17.0 | 14.5 | 14.6 | 15.8 | |||||
| P/BV | ? | 12.0 | 0.00 | 0.00 | 10.8 | 10.9 | 12.1 | |||
| EV/EBITDA | ? | 55.9 | 74.5 | 35.7 | 56.7 | |||||
| Debt/EBITDA | -2.36 | -3.98 | -1.89 | -2.85 | ||||||
| R&D/CAPEX, % | 228.3% | 456.9% | 623.6% | |||||||
| CAPEX/Revenue, % | 6.30% | 0.00% | 3.47% | 2.52% | ||||||
| ABIOMED shareholders | ||||||||||
